Compare WINA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | DVAX |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1993 | 2004 |
| Metric | WINA | DVAX |
|---|---|---|
| Price | $421.30 | $10.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 85.0K | ★ 1.7M |
| Earning Date | 10-15-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | $84,517,400.00 | ★ $330,514,000.00 |
| Revenue This Year | $7.05 | $24.63 |
| Revenue Next Year | $3.60 | $15.85 |
| P/E Ratio | $37.40 | ★ N/A |
| Revenue Growth | 3.35 | ★ 26.73 |
| 52 Week Low | $295.79 | $9.20 |
| 52 Week High | $527.37 | $14.63 |
| Indicator | WINA | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 51.72 |
| Support Level | $405.86 | $10.79 |
| Resistance Level | $437.10 | $11.10 |
| Average True Range (ATR) | 15.54 | 0.31 |
| MACD | 2.62 | -0.07 |
| Stochastic Oscillator | 62.43 | 35.79 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.